Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Squamous Cell Carcinoma of Head and Neck 14Head and Neck Neoplasms 11Glioblastoma 8Prostatic Neoplasms 7Carcinoma 6Rectal Neoplasms 5Pancreatic Neoplasms 5Gliosarcoma 5Carcinoma, Non-Small-Cell Lung 5Astrocytoma 5Neoplasm Metastasis 4Uterine Cervical Neoplasms 3Neoplasms 3Glioma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Oligodendroglioma 2Medulloblastoma 2Lymphoma, Follicular 2Lymphoma 2Liver Neoplasms 2Leukemia, Myeloid, Acute 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Esophageal Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1

Interventions

Cisplatin 2vactosertib 1fludarabine 1enzalutamide 1bintrafusp alfa protein, human 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Paclitaxel 1LY3300054 1Gemcitabine 1Fenretinide 1Cyclophosphamide 1Carboplatin 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Camurati-Engelmann Syndrome × Radiotherapy, Intensity-Modulated × Clear all
NCT02937272 2026-04-03

A Study of LY3200882 in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
223 enrolled

Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡